Female Sexual Dysfunction Treatment Market – By Drug (Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy), Disease (Dyspareunia, HSDD), Route of Administration (Oral, Parenteral, Topical), Distribution Channel – Global Forecast (2024 – 2032)

Female Sexual Dysfunction Treatment Market Size

Female Sexual Dysfunction Treatment Market size was valued at around USD 495.3 million in 2023 and is estimated to grow at 10% CAGR from 2024 to 2032. Female sexual dysfunction (FSD) treatment refers to the various medical, psychological, and lifestyle interventions aimed at addressing a range of sexual health issues and dysfunctions experienced by women.
 

FSD encompasses difficulties related to sexual desire, arousal, orgasm, and satisfaction that cause distress or interpersonal difficulties. Treatment approaches for FSD are personalized to each individual's needs and may include psychotherapy, hormonal therapy, medications such as phosphodiesterase inhibitors, pelvic floor exercises, couples therapy, sexual health testing, education and counseling, and lifestyle modifications.
 

The increasing advancements in medical technology in the field of female sexual dysfunction (FSD) treatment is a significant driving factors for the market. Furthermore, increasing awareness regarding female sexual health issues, growing focus towards women's health, and rising research & development activities, are the promoting factors fostering the growth of the market.

Female Sexual Dysfunction Treatment Market Trends

The landscape of female sexual dysfunction (FSD) treatment is undergoing a transformative shift propelled by a surge in research and development (R&D) activities aimed at addressing this prevalent yet often overlooked condition. As awareness grows and societal taboos surrounding sexual health diminish, researchers, healthcare professionals, and pharmaceutical companies are increasingly dedicating resources to unravelling the complexities of FSD and developing innovative treatment modalities.
 

• Increased R&D efforts lead to a deeper understanding of the underlying causes and mechanisms of FSD. This understanding is crucial for developing more effective treatment strategies.
   
• R&D activities foster innovation leading to the development of novel treatment options for FSD. This can include new medications, devices, and therapeutic approaches tailored specifically to address the various subtypes of FSD.
   
• Similarly, advancements in R&D enable personalized treatment approaches tailored to individual factors such as genetics, hormones, and psychology enhancing efficacy and patient satisfaction. Increased research awareness reduces societal stigma around FSD, encouraging more individuals to seek treatment without fear of judgment. Thus, escalating the growth of the market.
   

Female Sexual Dysfunction Treatment Market Analysis

Based on drug, the market is divided into flibanserin, bremelanotide, ospemifene, estrogen therapy, and other drugs. The estrogen therapy segment is estimated to account for USD 797.2 million by 2032.
 

• Estrogen therapy can help to alleviate vaginal dryness, itching, and discomfort are common symptoms of FSD. By restoring vaginal lubrication and elasticity estrogen therapy can enhance comfort and pleasure during sexual activity.
   
• It improves overall sexual satisfaction by addressing physiological factors contributing to FSD. By restoring vaginal health and libido women may experience greater pleasure and fulfillment in their sexual experiences.
   
• Further, estrogen therapy can be tailored to individual needs and preferences, allowing healthcare providers to adjust dosage and delivery methods based on factors such as age, symptoms, and medical history, thereby propelling the growth of the market.
   

Based on disease, the female sexual dysfunction treatment market is bifurcated into dyspareunia, hypoactive sexual desire disorder (HSDD), and other diseases. The dyspareunia segment accounted for USD 224.5 million in 2023.
 

• Treatment for dyspareunia aims to alleviate or reduce pain during intercourse, thereby improving sexual satisfaction and intimacy for affected individuals.
   
• Resolving dyspareunia can lead to improved sexual functioning including increased desire, arousal, and orgasmic response as individuals are no longer inhibited by pain during intercourse.
   
• Additionally, dyspareunia treatment may involve a multidisciplinary approach, incorporating interventions from various healthcare professionals such as gynecologists, physical therapists, sex therapists, and psychologists, ensuring comprehensive and holistic care.
   

Based on route of administration, the female sexual dysfunction treatment market is segmented into oral, parenteral, and topical. The parenteral segment held a market share of 38.4% in the year 2023.
 

• Parenteral administration allows for the rapid delivery of medication into the bloodstream leading to quicker onset of therapeutic effects compared to oral medications.
   
• By bypassing the digestive system parenteral administration can enhance the bioavailability of medications ensuring a higher proportion of the active ingredient reaches the target tissues or organs involved in sexual function.
   
• Further, parenteral administration enables precise control over dosage, allowing healthcare providers to tailor treatment regimens to individual needs and optimize therapeutic outcomes for FSD, thereby expanding the growth of the market.
   

Based on distribution channel, the female sexual dysfunction treatment market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held a market size of USD 237.2 million in 2023.
 

• Hospital pharmacies may have access to a broader range of medications used in the treatment of FSD including less common or specialized drugs that may not be readily available in retail pharmacies. This ensures that patients have access to the most appropriate and effective treatments for their condition.
   
• They work closely with healthcare providers including gynecologists, endocrinologists, and sexual health specialists to ensure that patients with FSD receive comprehensive and coordinated care. This collaboration allows for the optimization of treatment regimens and the management of potential drug interactions or side effects.
   
• Further, hospital pharmacies may have access to a broader range of medications used in the treatment of FSD including less common or specialized drugs that may not be readily available in retail pharmacies. This ensures that patients have access to the most appropriate and effective treatments for their condition.
   

U.S. female sexual dysfunction treatment market is anticipated to grow at CAGR of 9.7% during the analysis timeframe.
 

• The country has a well-developed healthcare infrastructure with modern facilities, advanced medical technology, and highly trained healthcare professionals. This enables the delivery of high-quality care for FSD including comprehensive diagnostic evaluations and access to cutting-edge treatment modalities.
   
• U.S. is a hub for medical research and innovation with numerous academic institutions, research centers, and pharmaceutical companies dedicated to advancing the understanding and treatment of FSD. Ongoing research initiatives contribute to the development of novel therapies, treatment guidelines, and evidence-based practices.
   

UK is anticipated to witness robust growth in the global female sexual dysfunction treatment market.
 

• The UK's publicly funded healthcare system the National Health Service (NHS), provides universal access to healthcare services including diagnosis and treatment for FSD. Patients can access a range of sexual health services, including specialist clinics and counseling, without the barrier of cost.
   

China female sexual dysfunction treatment market is anticipated to witness lucrative growth between 2024 – 2032.
 

• China has a growing number of research institutions and academic centers dedicated to studying sexual health and FSD. Ongoing research efforts contribute to a deeper understanding of the underlying causes of FSD, and the development of innovative treatment approaches tailored to the Chinese population.
   
• The Chinese government has implemented initiatives to address sexual health issues, including FSD as part of broader public health efforts. This includes promoting sexual education, improving access to healthcare services, and supporting research on sexual health-related topics, thereby boosting market growth.
   

South Korea female sexual dysfunction treatment market is expected to grow significantly over the years.
 

• South Korea boasts a modern healthcare infrastructure with state-of-the-art medical facilities, advanced technology, and highly trained healthcare professionals. This enables the delivery of high-quality care for FSD, including comprehensive diagnostic evaluations and access to cutting-edge treatment modalities.
   
• Additionally, the country has a rich tradition of using traditional Korean medicine (TKM) to treat various health conditions, including sexual dysfunction. TKM approaches such as acupuncture, herbal medicine, and dietary therapy, are often integrated into FSD treatment regimens, providing patients with additional therapeutic options.
   

Female Sexual Dysfunction Treatment Market Share

The female sexual dysfunction treatment industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products and services based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.
 

Female Sexual Dysfunction Treatment Market Companies

Some of the eminent market participants operating in the female sexual dysfunction treatment industry include:

• Apricus Biosciences, Inc.    
• Cipla Limited
• Freya Pharma Solutions
• GSK plc        
• Lawley Pharmaceuticals Pty Ltd.    
• Merck & Co., Inc.     
• Millicent Pharma Limited    
• Novo Nordisk
• Pfizer, Inc.    
• Sprout Pharmaceuticals, Inc.

Female Sexual Dysfunction Treatment Industry News:

• In May 2020, Millicent Pharma Limited acquired the U.S. commercial rights to Intrarosa (prasterone) from AMAG Pharmaceuticals, Inc. This acquisition diversified Millicent Pharma's product offerings and provided an opportunity to address unmet medical needs in the field of women's health, ultimately benefiting the company's growth and strategic objectives.
   

The female sexual dysfunction treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug

• Flibanserin
• Bremelanotide
• Ospemifene
• Estrogen therapy
• Other drugs

Market, By Disease

• Dyspareunia
• Hypoactive sexual desire disorder (HSDD)
• Other diseases

Market, By Route of Administration

• Oral
• Parenteral
• Topical

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa